Header

UZH-Logo

Maintenance Infos

Scalp psoriasis: European consensus on grading and treatment algorithm


Ortonne, J; Chimenti, S; Luger, T; Puig, L; Reid, F; Trüeb, R M (2009). Scalp psoriasis: European consensus on grading and treatment algorithm. Journal of the European Academy of Dermatology and Venereology, 23(12): 1435- 1444.

Abstract

The scalp is a common site of involvement of psoriasis and, for many patients, is a challenging aspect of their disease. This can be attributed not only to the scaling, itching and cosmetic embarrassment that go with scalp psoriasis, but also to the fact that the scalp skin is relatively inaccessible, making topical therapies difficult to apply. The proximity of sensitive facial skin can also limit the use of potentially irritating topical treatments. Nevertheless, the specific challenges of scalp psoriasis are often neglected by treatment guidelines. This paper summarizes the discussions that took place at an international conference of experts convened in Geneva, Switzerland, in March 2008. The objective of the meeting was to review the available treatments for scalp psoriasis in terms of efficacy, safety, convenience, and the implications for patient compliance with treatment. In addition, definitions of mild, moderate and severe scalp psoriasis were agreed. This paper presents a treatment algorithm that includes recommendations for patients in all three categories. It considers the role of potent topical corticosteroids, vitamin D3 derivatives, salicylic acid preparations, and photo- and radiotherapy, as well as systemic therapies, including newer biological agents, for patients with widespread psoriasis with scalp involvement. Data from clinical trials indicate that a potent topical corticosteroid in a short-contact formulation is the most appropriate treatment for most patients with scalp psoriasis. Conflicts of interest The consensus meeting of European experts on management of scalp psoriasis has been organized by LEO Pharmaceuticals. J.P. Ortonne has served as a paid speaker and consultant for LEO Pharma. J.P. Ortonne is also a paid consultant for Galderma. Lluís Puig has participated as Principal Investigator in a clinical trial sponsored by Galderma. Galderma has provided funding to support the work in this project.

Abstract

The scalp is a common site of involvement of psoriasis and, for many patients, is a challenging aspect of their disease. This can be attributed not only to the scaling, itching and cosmetic embarrassment that go with scalp psoriasis, but also to the fact that the scalp skin is relatively inaccessible, making topical therapies difficult to apply. The proximity of sensitive facial skin can also limit the use of potentially irritating topical treatments. Nevertheless, the specific challenges of scalp psoriasis are often neglected by treatment guidelines. This paper summarizes the discussions that took place at an international conference of experts convened in Geneva, Switzerland, in March 2008. The objective of the meeting was to review the available treatments for scalp psoriasis in terms of efficacy, safety, convenience, and the implications for patient compliance with treatment. In addition, definitions of mild, moderate and severe scalp psoriasis were agreed. This paper presents a treatment algorithm that includes recommendations for patients in all three categories. It considers the role of potent topical corticosteroids, vitamin D3 derivatives, salicylic acid preparations, and photo- and radiotherapy, as well as systemic therapies, including newer biological agents, for patients with widespread psoriasis with scalp involvement. Data from clinical trials indicate that a potent topical corticosteroid in a short-contact formulation is the most appropriate treatment for most patients with scalp psoriasis. Conflicts of interest The consensus meeting of European experts on management of scalp psoriasis has been organized by LEO Pharmaceuticals. J.P. Ortonne has served as a paid speaker and consultant for LEO Pharma. J.P. Ortonne is also a paid consultant for Galderma. Lluís Puig has participated as Principal Investigator in a clinical trial sponsored by Galderma. Galderma has provided funding to support the work in this project.

Statistics

Citations

27 citations in Web of Science®
27 citations in Scopus®
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2009
Deposited On:17 Mar 2010 14:16
Last Modified:05 Apr 2016 13:54
Publisher:Wiley-Blackwell
ISSN:0926-9959
Publisher DOI:https://doi.org/10.1111/j.1468-3083.2009.03372.x
PubMed ID:19614856

Download

Full text not available from this repository.
View at publisher

TrendTerms

TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents.
You can navigate and zoom the map. Mouse-hovering a term displays its timeline, clicking it yields the associated documents.

Author Collaborations